Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지
DOI QR코드

DOI QR Code

Empirical medical therapy in idiopathic male infertility: Promise or panacea?

  • Jung, Jae Hung (Department of Urology, Yonsei University Wonju College of Medicine) ;
  • Seo, Ju Tae (Department of Urology, Cheil General Hospital, Kwandong University College of Medicine)
  • Received : 2014.07.25
  • Accepted : 2014.09.05
  • Published : 2014.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Male factors account for 20%-50% of cases of infertility and in 25% of cases, the etiology of male infertility is unknown. Effective treatments are well-established for hypogonadotropic hypogonadism, male accessory gland infection, retrograde ejaculation, and positive antisperm antibody. However, the appropriate treatment for idiopathic male infertility is unclear. Empirical medical treatment (EMT) has been used in men with idiopathic infertility and can be divided into two categories based on the mode of action: hormonal treatment and antioxidant supplementation. Hormonal medications consist of gonadotropins, androgens, estrogen receptor blockers, and aromatase inhibitors. Antioxidants such as vitamins, zinc, and carnitines have also been widely used to reduce oxidative stress-induced spermatozoa damage. Although scientifically acceptable evidence of EMT is limited because of the lack of large, randomized, controlled studies, recent systematic reviews with meta-analyses have shown that the administration of gonadotropins, anti-estrogens, and oral antioxidants results in a significant increase in the live birth rate compared with control treatments. Therefore, all physicians who treat infertility should bear in mind that EMT can improve semen parameters and subsequent fertility potential through natural intercourse.

Keywords

References

  1. Gnoth C, Godehardt E, Frank-Herrmann P, Friol K, Tigges J, Freundl G. Definition and prevalence of subfertility and infertility. Hum Reprod 2005;20:1144-7. https://doi.org/10.1093/humrep/deh870
  2. Irvine DS. Epidemiology and aetiology of male infertility. Hum Reprod 1998;13 Suppl 1:33-44.
  3. Sabanegh EJ, Agarwal A. Male infertility. In: Campbell MF, Walsh PC, Wein AJ, editor. Campbell-Walsh urology. 10th ed. Philadelphia: Saunders Elsevier; 2012. p. 616-47.
  4. Ko EY, Siddiqi K, Brannigan RE, Sabanegh ES Jr. Empirical medical therapy for idiopathic male infertility: a survey of the American Urological Association. J Urol 2012;187:973-8. https://doi.org/10.1016/j.juro.2011.10.137
  5. Kumar R, Gautam G, Gupta NP. Drug therapy for idiopathic male infertility: rationale versus evidence. J Urol 2006;176:1307-12. https://doi.org/10.1016/j.juro.2006.06.006
  6. Rittenberg V, El-Toukhy T. Medical treatment of male infertility. Hum Fertil (Camb) 2010;13:208-16. https://doi.org/10.3109/14647273.2010.534833
  7. Valenti D, La Vignera S, Condorelli RA, Rago R, Barone N, Vicari E, et al. Follicle-stimulating hormone treatment in normogonadotropic infertile men. Nat Rev Urol 2013;10:55-62. https://doi.org/10.1038/nrurol.2012.234
  8. Iacono F, Barra S, Montano L, Lotti T. Value of high-dose pure FSH in the treatment of idiopathic male infertility. J Urol (Paris) 1996;102:81-4.
  9. Foresta C, Bettella A, Ferlin A, Garolla A, Rossato M. Evidence for a stimulatory role of follicle-stimulating hormone on the spermatogonial population in adult males. Fertil Steril 1998;69:636-42. https://doi.org/10.1016/S0015-0282(98)00008-9
  10. Paradisi R, Busacchi P, Seracchioli R, Porcu E, Venturoli S. Effects of high doses of recombinant human follicle-stimulating hormone in the treatment of male factor infertility: results of a pilot study. Fertil Steril 2006;86:728-31. https://doi.org/10.1016/j.fertnstert.2006.02.087
  11. Arnaldi G, Balercia G, Barbatelli G, Mantero F. Effects of long-term treatment with human pure follicle-stimulating hormone on semen parameters and sperm-cell ultrastructure in idiopathic oligoteratoasthenozoospermia. Andrologia 2000;32:155-61. https://doi.org/10.1046/j.1439-0272.2000.00358.x
  12. Piomboni P, Serafini F, Gambera L, Musacchio C, Collodel G, Morgante G, et al. Sperm aneuploidies after human recombinant follicle stimulating hormone therapy in infertile males. Reprod Biomed Online 2009;18:622-9. https://doi.org/10.1016/S1472-6483(10)60005-3
  13. Attia AM, Abou-Setta AM, Al-Inany HG. Gonadotrophins for idiopathic male factor subfertility. Cochrane Database Syst Rev 2013;8:CD005071.
  14. Knuth UA, Honigl W, Bals-Pratsch M, Schleicher G, Nieschlag E. Treatment of severe oligospermia with human chorionic gonadotropin/human menopausal gonadotropin: a placebo-controlled, double blind trial. J Clin Endocrinol Metab 1987;65:1081-7. https://doi.org/10.1210/jcem-65-6-1081
  15. Kamischke A, Behre HM, Bergmann M, Simoni M, Schafer T, Nieschlag E. Recombinant human follicle stimulating hormone for treatment of male idiopathic infertility: a randomized, double-blind, placebo-controlled, clinical trial. Hum Reprod 1998;13:596-603. https://doi.org/10.1093/humrep/13.3.596
  16. Foresta C, Bettella A, Garolla A, Ambrosini G, Ferlin A. Treatment of male idiopathic infertility with recombinant human folliclestimulating hormone: a prospective, controlled, randomized clinical study. Fertil Steril 2005;84:654-61. https://doi.org/10.1016/j.fertnstert.2005.03.055
  17. Matorras R, Perez C, Corcostegui B, Pijoan JI, Ramon O, Delgado P, et al. Treatment of the male with follicle-stimulating hormone in intrauterine insemination with husband's spermatozoa: a randomized study. Hum Reprod 1997;12:24-8. https://doi.org/10.1093/humrep/12.1.24
  18. Baccetti B, Piomboni P, Bruni E, Capitani S, Gambera L, Moretti E, et al. Effect of follicle-stimulating hormone on sperm quality and pregnancy rate. Asian J Androl 2004;6:133-7.
  19. Vandekerckhove P, Lilford R, Vail A, Hughes E. Androgens versus placebo or no treatment for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev 1996;18:CD000150.
  20. Gregoriou O, Papadias C, Gargaropoulos A, Konidaris S, Kontogeorgi Z, Kalampokas E. Treatment of idiopathic infertility with testosterone undecanoate. A double blind study. Clin Exp Obstet Gynecol 1993;20:9-12.
  21. Liu PY, Handelsman DJ. The present and future state of hormonal treatment for male infertility. Hum Reprod Update 2003;9:9-23. https://doi.org/10.1093/humupd/dmg002
  22. Kamischke A, Nieschlag E. Analysis of medical treatment of male infertility. Hum Reprod 1999;14 Suppl 1:1-23.
  23. Fronczak CM, Kim ED, Barqawi AB. The insults of illicit drug use on male fertility. J Androl 2012;33:515-28. https://doi.org/10.2164/jandrol.110.011874
  24. de Souza GL, Hallak J. Anabolic steroids and male infertility: a comprehensive review. BJU Int 2011;108:1860-5. https://doi.org/10.1111/j.1464-410X.2011.10131.x
  25. Patankar SS, Kaore SB, Sawane MV, Mishra NV, Deshkar AM. Effect of clomiphene citrate on sperm density in male partners of infertile couples. Indian J Physiol Pharmacol 2007;51:195-8.
  26. Hayes FJ, Seminara SB, Decruz S, Boepple PA, Crowley WF Jr. Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback. J Clin Endocrinol Metab 2000;85:3027-35.
  27. Vandekerckhove P, Lilford R, Vail A, Hughes E. Clomiphene or tamoxifen for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev 1996;4:CD000151.
  28. Chua ME, Escusa KG, Luna S, Tapia LC, Dofitas B, Morales M. Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis. Andrology 2013;1:749-57. https://doi.org/10.1111/j.2047-2927.2013.00107.x
  29. Clark RV, Sherins RJ. Treatment of men with idiopathic oligozoospermic infertility using the aromatase inhibitor, testolactone. Results of a double-blinded, randomized, placebo-controlled trial with crossover. J Androl 1989;10:240-7. https://doi.org/10.1002/j.1939-4640.1989.tb00094.x
  30. Pavlovich CP, King P, Goldstein M, Schlegel PN. Evidence of a treatable endocrinopathy in infertile men. J Urol 2001;165:837-41. https://doi.org/10.1016/S0022-5347(05)66540-8
  31. Raman JD, Schlegel PN. Aromatase inhibitors for male infertility. J Urol 2002;167:624-9. https://doi.org/10.1016/S0022-5347(01)69099-2
  32. Lee JS, Park YS, Lee JS, Seo JT. Appropriate Testosterone-to-Estradiol Ratios for Aromatase Inhibitor Usage in Oligoasthenospermic Men. Korean J Androl 2004;22:31-5.
  33. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007;39:44-84. https://doi.org/10.1016/j.biocel.2006.07.001
  34. Agarwal A, Virk G, Ong C, du Plessis SS. Effect of oxidative stress on male reproduction. World J Mens Health 2014;32:1-17. https://doi.org/10.5534/wjmh.2014.32.1.1
  35. Sanocka D, Kurpisz M. Reactive oxygen species and sperm cells. Reprod Biol Endocrinol 2004;2:12. https://doi.org/10.1186/1477-7827-2-12
  36. Sharma RK, Agarwal A. Role of reactive oxygen species in male infertility. Urology 1996;48:835-50. https://doi.org/10.1016/S0090-4295(96)00313-5
  37. Chen H, Zhao HX, Huang XF, Chen GW, Yang ZX, Sun WJ, et al. Does high load of oxidants in human semen contribute to male factor infertility? Antioxid Redox Signal 2012;16:754-9. https://doi.org/10.1089/ars.2011.4461
  38. Jensen TK, Skakkebaek NE, Jorgensen N, Jensen MB, Juul A. Antioxidants and male subfertility--a survey of a Cochrane review. Ugeskr Laeger 2011;173:3253-5.
  39. Suleiman SA, Ali ME, Zaki ZM, el-Malik EM, Nasr MA. Lipid peroxidation and human sperm motility: protective role of vitamin E. J Androl 1996;17:530-7.
  40. Kessopoulou E, Powers HJ, Sharma KK, Pearson MJ, Russell JM, Cooke ID, et al. A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertil Steril 1995;64:825-31. https://doi.org/10.1016/S0015-0282(16)57861-3
  41. Showell MG, Brown J, Yazdani A, Stankiewicz MT, Hart RJ. Antioxidants for male subfertility. Cochrane Database Syst Rev 2011:CD007411.
  42. Dawson EB, Harris WA, Rankin WE, Charpentier LA, McGanity WJ. Effect of ascorbic acid on male fertility. Ann N Y Acad Sci 1987;498:312-23. https://doi.org/10.1111/j.1749-6632.1987.tb23770.x
  43. Akmal M, Qadri JQ, Al-Waili NS, Thangal S, Haq A, Saloom KY. Improvement in human semen quality after oral supplementation of vitamin C. J Med Food 2006;9:440-2. https://doi.org/10.1089/jmf.2006.9.440
  44. Bray TM, Bettger WJ. The physiological role of zinc as an antioxidant. Free Radic Biol Med 1990;8:281-91. https://doi.org/10.1016/0891-5849(90)90076-U
  45. Zago MP, Oteiza PI. The antioxidant properties of zinc: interactions with iron and antioxidants. Free Radic Biol Med 2001;31:266-74. https://doi.org/10.1016/S0891-5849(01)00583-4
  46. Gavella M, Lipovac V, Vucic M, Sverko V. In vitro inhibition of superoxide anion production and superoxide dismutase activity by zinc in human spermatozoa. Int J Androl 1999;22:266-74. https://doi.org/10.1046/j.1365-2605.1999.00179.x
  47. Turk S, Mandar R, Mahlapuu R, Viitak A, Punab M, Kullisaar T. Male infertility: decreased levels of selenium, zinc and antioxidants. J Trace Elem Med Biol 2014;28:179-85. https://doi.org/10.1016/j.jtemb.2013.12.005
  48. Wong WY, Merkus HM, Thomas CM, Menkveld R, Zielhuis GA, Steegers-Theunissen RP. Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebocontrolled trial. Fertil Steril 2002;77:491-8. https://doi.org/10.1016/S0015-0282(01)03229-0
  49. Omu AE, Dashti H, Al-Othman S. Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. Eur J Obstet Gynecol Reprod Biol 1998;79:179-84. https://doi.org/10.1016/S0301-2115(97)00262-5
  50. Omu AE, Al-Azemi MK, Kehinde EO, Anim JT, Oriowo MA, Mathew TC. Indications of the mechanisms involved in improved sperm parameters by zinc therapy. Med Princ Pract 2008;17:108-16. https://doi.org/10.1159/000112963
  51. Jeulin C, Lewin LM. Role of free L-carnitine and acetyl-L-carnitine in post-gonadal maturation of mammalian spermatozoa. Hum Reprod Update 1996;2:87-102. https://doi.org/10.1093/humupd/2.2.87
  52. Zhou X, Liu F, Zhai S. Effect of L-carnitine and/or L-acetyl-carnitine in nutrition treatment for male infertility: a systematic review. Asia Pac J Clin Nutr 2007;16 Suppl 1:383-90.
  53. Balercia G, Regoli F, Armeni T, Koverech A, Mantero F, Boscaro M. Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertil Steril 2005;84:662-71. https://doi.org/10.1016/j.fertnstert.2005.03.064
  54. Lenzi A, Sgro P, Salacone P, Paoli D, Gilio B, Lombardo F, et al. A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia. Fertil Steril 2004;81:1578-84. https://doi.org/10.1016/j.fertnstert.2003.10.034
  55. Peivandi S, Abasali K, Narges M. Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. J Reprod Infertil 2010;10:331.
  56. Mancini A, Conte B, De Marinis L, Hallgass ME, Pozza D, Oradei A, et al. Coenzyme Q10 levels in human seminal fluid: diagnostic and clinical implications. Mol Aspects Med 1994;15 Suppl:s249-55. https://doi.org/10.1016/0098-2997(94)90035-3
  57. Lafuente R, Gonzalez-Comadran M, Sola I, Lopez G, Brassesco M, Carreras R, et al. Coenzyme Q10 and male infertility: a meta-analysis. J Assist Reprod Genet 2013;30:1147-56. https://doi.org/10.1007/s10815-013-0047-5
  58. Safarinejad MR, Safarinejad S. Efficacy of selenium and/or N-ace tyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. J Urol 2009;181:741-51.
  59. Wang C, Chan CW, Wong KK, Yeung KK. Comparison of the effectiveness of placebo, clomiphene citrate, mesterolone, pentoxifylline, and testosterone rebound therapy for the treatment of idiopathic oligospermia. Fertil Steril 1983;40:358-65. https://doi.org/10.1016/S0015-0282(16)47300-0
  60. Zavaczki Z, Szollosi J, Kiss SA, Koloszar S, Fejes I, Kovacs L, et al. Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study. Magnes Res 2003;16:131-6.
  61. Adamopoulos DA, Pappa A, Billa E, Nicopoulou S, Koukkou E, Michopoulos J. Effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in men with idiopathic oligozoospermia. Fertil Steril 2003;80:914-20. https://doi.org/10.1016/S0015-0282(03)01123-3
  62. Adamopoulos DA, Nicopoulou S, Kapolla N, Karamertzanis M, Andreou E. The combination of testosterone undecanoate with tamoxifen citrate enhances the effects of each agent given independently on seminal parameters in men with idiopathic oligozoospermia. Fertil Steril 1997;67:756-62. https://doi.org/10.1016/S0015-0282(97)81379-9
  63. Dohle GR, Colpi GM, Hargreave TB, Papp GK, Jungwirth A, Weidner W, et al. EAU guidelines on male infertility. Eur Urol 2005;48:703-11. https://doi.org/10.1016/j.eururo.2005.06.002
  64. Jungwirth A, Giwercman A, Tournaye H, Diemer T, Kopa Z, Dohle G, et al. European Association of Urology guidelines on Male Infertility: the 2012 update. Eur Urol 2012;62:324-32. https://doi.org/10.1016/j.eururo.2012.04.048
  65. Moradi M, Moradi A, Alemi M, Ahmadnia H, Abdi H, Ahmadi A, et al. Safety and efficacy of clomiphene citrate and L-carnitine in idiopathic male infertility: a comparative study. Urol J 2010;7:188-93.
  66. Ghanem H, Shaeer O, El-Segini A. Combination clomiphene citrate and antioxidant therapy for idiopathic male infertility: a randomized controlled trial. Fertil Steril 2010;93:2232-5. https://doi.org/10.1016/j.fertnstert.2009.01.117
  67. Paradiso Galatioto G, Gravina GL, Angelozzi G, Sacchetti A, Innominato PF, Pace G, et al. May antioxidant therapy improve sperm parameters of men with persistent oligospermia after retrograde embolization for varicocele? World J Urol 2008;26:97-102. https://doi.org/10.1007/s00345-007-0218-z
  68. Greco E, Iacobelli M, Rienzi L, Ubaldi F, Ferrero S, Tesarik J. Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. J Androl 2005;26:349-53. https://doi.org/10.2164/jandrol.04146
  69. Scott R, MacPherson A, Yates RW, Hussain B, Dixon J. The effect of oral selenium supplementation on human sperm motility. Br J Urol 1998;82:76-80. https://doi.org/10.1046/j.1464-410x.1998.00683.x
  70. Rolf C, Cooper TG, Yeung CH, Nieschlag E. Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Hum Reprod 1999;14:1028-33. https://doi.org/10.1093/humrep/14.4.1028
  71. Derman SG, Adashi EY. Adverse effects of fertility drugs. Drug Saf 1994;11:408-21. https://doi.org/10.2165/00002018-199411060-00003
  72. Cavallini G, Ferraretti AP, Gianaroli L, Biagiotti G, Vitali G. Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocele-associated oligoasthenospermia. J Androl 2004;25:761-70. https://doi.org/10.1002/j.1939-4640.2004.tb02853.x
  73. Kim JW, Moon DG. Diagnosis and treatment of sexual dysfunctions in late-onset hypogonadism. Korean J Urol 2011;52:725-35. https://doi.org/10.4111/kju.2011.52.11.725
  74. Jan Z, Pfeifer M, Zorn B. Reversible testosterone-induced azoospermia in a 45-year-old man attending an infertility outpatient clinic. Andrologia 2012;44 Suppl 1:823-5. https://doi.org/10.1111/j.1439-0272.2011.01192.x
  75. Nudell DM, Monoski MM, Lipshultz LI. Common medications and drugs: how they affect male fertility. Urol Clin North Am 2002;29:965-73. https://doi.org/10.1016/S0094-0143(02)00079-4

Cited by

  1. Sperm Count Improvement in a Cancer-Surviving Patient vol.8, pp.2, 2014, https://doi.org/10.1159/000438668
  2. FSH treatment of male idiopathic infertility improves pregnancy rate: a meta-analysis vol.4, pp.3, 2014, https://doi.org/10.1530/ec-15-0050
  3. An evidence‐based approach to medicinal plants for the treatment of sperm abnormalities in traditional Persian medicine vol.48, pp.8, 2014, https://doi.org/10.1111/and.12676
  4. Association between periodontal status and idiopathic male infertility vol.58, pp.2, 2014, https://doi.org/10.2334/josnusd.15-0586
  5. Correlation of Seminal Plasma Total Antioxidant Capacity and Malondialdehyde Levels With Sperm Parameters in Men With Idiopathic Infertility vol.4, pp.1, 2014, https://doi.org/10.17795/ajmb-29736
  6. Classification, causes, diagnosis and treatment of male infertility: a review vol.17, pp.2, 2017, https://doi.org/10.1007/s13596-017-0269-7
  7. Conservative Nonhormonal Options for the Treatment of Male Infertility: Antibiotics, Anti-Inflammatory Drugs, and Antioxidants vol.2017, pp.None, 2014, https://doi.org/10.1155/2017/4650182
  8. Sperm DNA fragmentation testing: where we stand in 2017 vol.6, pp.4, 2014, https://doi.org/10.21037/tau.2017.05.25
  9. The treatment effect of novel hGHRH homodimer to male infertility hamster vol.22, pp.6, 2018, https://doi.org/10.4196/kjpp.2018.22.6.637
  10. Effects of Withania somnifera on Reproductive System: A Systematic Review of the Available Evidence vol.2018, pp.None, 2014, https://doi.org/10.1155/2018/4076430
  11. The influence of BESTFertil towards male reproductive function in idiopathic fertility vol.19, pp.4, 2018, https://doi.org/10.17650/2070-9781-2018-19-4-54-59
  12. Male Oxidative Stress Infertility (MOSI): Proposed Terminology and Clinical Practice Guidelines for Management of Idiopathic Male Infertility vol.37, pp.3, 2014, https://doi.org/10.5534/wjmh.190055
  13. Medikamentöse Therapie primär nichthormonell bedingter männlicher Fertilitätsstörungen vol.17, pp.4, 2014, https://doi.org/10.1007/s10304-019-00273-2
  14. The current status and future of andrology: A consensus report from the Cairo workshop group vol.8, pp.1, 2014, https://doi.org/10.1111/andr.12720
  15. Treatment of male hypogonadism partially reverses oxidative stress in patients with hypogonadism vol.67, pp.9, 2014, https://doi.org/10.1507/endocrj.ej20-0133
  16. Evaluating the Combination of Human Chorionic Gonadotropin and Clomiphene Citrate in Treatment of Male Hypogonadotropic Hypogonadism: A Prospective Study vol.13, pp.None, 2021, https://doi.org/10.2147/rru.s315056
  17. Computational and Preclinical Evidence of Anti-ischemic Properties of L-Carnitine-Rich Supplement via Stimulation of Anti-inflammatory and Antioxidant Events in Testicular Torsed Rats vol.2021, pp.None, 2014, https://doi.org/10.1155/2021/5543340
  18. Lack of trusted diagnostic tools for undetermined male infertility vol.38, pp.2, 2021, https://doi.org/10.1007/s10815-020-02037-5
  19. Do lifestyle practices impede male fertility? vol.53, pp.1, 2014, https://doi.org/10.1111/and.13595
  20. Efficacy of Non-Testosterone-Based Treatment in Hypogonadal Men: A Review vol.9, pp.3, 2021, https://doi.org/10.1016/j.sxmr.2020.08.003
  21. MiR-181a Promotes Spermatogenesis by Targeting the S6K1 Pathway vol.14, pp.3, 2021, https://doi.org/10.15283/ijsc21001
  22. Declining levels of miR-382-3p at puberty trigger the onset of spermatogenesis vol.26, pp.None, 2014, https://doi.org/10.1016/j.omtn.2021.07.001